Goldman Sachs Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $198
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $174 to $198.
August 02, 2024 | 4:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs has maintained a Neutral rating on Alnylam Pharmaceuticals but raised the price target from $174 to $198, indicating a positive outlook on the stock's potential.
The raised price target from $174 to $198 by Goldman Sachs suggests a positive outlook for Alnylam Pharmaceuticals, despite maintaining a Neutral rating. This could lead to a short-term increase in stock price as investors react to the higher target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100